A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques.

ABSTRACT:

Background

Human monoclonal antibody (mAb) treatments are promising for COVID-19 prevention or therapy. The pre-exposure prophylactic efficacy of neutralizing antibodies that are engineered with mutations to extend their persistence in human serum and the neutralizing antibody titer in serum required for protection against SARS-CoV-2 infection remain poorly characterized.

Methods

The Fc region of two neutralizing mAbs (COV2-2130 and COV2-2381) targeting non-overlapping epitopes on the receptor binding domain of SARS-CoV-2 spike protein was engineered to extend their persistence in humans and reduce interactions with Fc gamma receptors. We assessed protection by individual antibodies or a combination of the two antibodies (designated ADM03820) given prophylactically by an int

SUBMITTER: Cobb RR 

PROVIDER: S-EPMC8810411 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature